Brief timeline and flunding history
© 2011 Fluxion Biosciences. All rights reserved.
Fluxion today
•
Company:
– Venture backed since Dec 2007
– 4 products commercialized and selling globally
– Segment: Biotools
– Over 100 units installed
•
Products: instruments and consumables
– BioFlux System for cell-cell interactions
– IonFlux Automated Patch Clamp System
– IsoFlux rare cell isolation platform – under development
BioFlux 200
BioFlux 1000
© 2011 Fluxion Biosciences. All rights reserved.
IonFlux-16
IonFlux HT
Page 2
Partial customer list
Johnson & Johnson
© 2011 Fluxion Biosciences. All rights reserved.
Page 3
IonFlux applications
• Compound profiling
– Dose response measurements
– Hit confirmation
– Single concentration screening
• Mutant screening
– Evaluate functional changes dependent on mutations
– Record responses from up to 32 distinct mutants (8 for IF-HT)
• Structure-function studies
–
–
–
–
Determine the effect of mutations on channel function
Characterize expression for differentiated stem cells
Recording endogenously expressed ion channels
Screen clones based on ion channel density
© 2011 Fluxion Biosciences. All rights reserved.
Page 4
IonFlux Technology for APC
- Best in Class
• High quality data
– G-seal quality recordings
– Ensemble recording for improved
success rate
• Cost effective
– Perform APC for about the cost of an
MPC setup
• Simple to use
– Ease of use of a ‘plate reader’
– Relevance of patch clamp data
– Table top unit
• Reliable
– No robotics required
– Only two moving parts
© 2011 Fluxion Biosciences. All rights reserved.
Page 5
Ensemble vs. single cell recording
• Ensembles average signals over 20 patched cells (16
ensembles per plate, left panel)
• The new single cell consumable records from one cell per
channel (16 cells per plate for IF-16, right panel)
• The single cell consumable utilizes the same hardware
20-cell ensemble
© 2011 Fluxion Biosciences. All rights reserved.
Single cell
Page 6
Well-Plate Integrated Microfluidics
Well-plate integrated microfluidics (WPM) utilizes standard 96- and 384well plates, but the bottom of the plate is replaced with a microfluidic
network interconnected between the wells.
© 2010
2011 Fluxion Biosciences. All rights reserved.
Page 7
* Sample customer slide – Pfizer UK
© 2011 Fluxion Biosciences. All rights reserved.
Page 8
High Level Timeline
Grant 2 Ph1
Founded
Grant 2 Ph2
2006
2007
2008
Grant 1 Ph2
Grant 1 Ph1
2009
2010
2011
IonFlux product
launch
BioFlux product
launch
Series A
© 2011 Fluxion Biosciences. All rights reserved.
Series B
Page 9
Grant pipeline and success rates
© 2011 Fluxion Biosciences. All rights reserved.
Page 10
SBIR: the good, the bad and the ugly
• The good:
– Non-dilutive capital!
– Can be the catalyst for new projects, encourages
innovation
– Early $$, which are the hardest
• The bad:
– Long timelines: 9 mo. from application to funding
– <200k is low capital for Phase I awards
– Can be a distraction from the central mission
• The ugly:
– Review process dependent on random events
– In our case, projects with the greatest commercial
worth didn’t get funded
© 2011 Fluxion Biosciences. All rights reserved.
Page 11